ENOV
Enovis Corporation26.07
-0.47-1.77%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Execution miss admitted; Arvis rollout detailed.
Q&A candidly pinned Q4's miss on execution slips amid Christmas timing, not market woes—a rare admission underscoring commercial discipline as priority one. Management detailed Arvis's 2026 phased rollout via flexible models to boost implants over capital sales, plus hip upside from Nebula and incoming Optimus. Debt reduction trumps tuck-ins absent generational deals, while One Enovis eyes sales synergies and shared services. Analysts flagged cash flow steps and P&R growth; replies affirmed conservative guidance with productivity tailwinds. We just didn't execute in Q4. Tone stays upbeat on innovation runway; investors will eye execution delivery.
Key Stats
Market Cap
1.49BP/E (TTM)
-Basic EPS (TTM)
-24.36Dividend Yield
0%Recent Filings
8-K
Enovis grows sales, books impairment
Enovis posted full-year 2025 net sales of $2.2B, up 7% reported and 6% organic, driven by 10% Recon growth yet flat P&R. A $1.05B goodwill impairment charge—triggered by stock price drops—swung net loss to $1.18B, masking $403M adjusted EBITDA. 2026 outlook eyes $2.31-2.37B revenue. Impairment flags valuation risks.
10-K
FY2025 results
Enovis Corporation's FY2025 net sales rose 6.7% to $2.25B, driven by 5.9% existing business growth and 1.4% favorable FX, with Recon up 10% on strong volumes while P&R gained 3.5% despite $17M divestiture drag. Q4 peaked seasonally, but goodwill impairments totaling $1.05B ($388M P&R, $662M Recon) hammered results amid sustained share price declines, yielding a $1.18B net loss. Adjusted EBITDA held steady at 17.9% margin ($403M), reflecting Recon's 21.6% and P&R's 14.3%. Debt rose to $1.30B post-$300M term loan expansion, yet liquidity endures with $943M revolver capacity. Q4 accelerated Recon volumes, but impairments stalled momentum.
8-K
Enovis at JPM Conference
Enovis Corporation is presenting at the 44th Annual J.P. Morgan Healthcare Conference today, January 12, 2026, at 4:30 p.m. PST. Management's live webcast and materials are accessible at www.enovis.com, with replay to follow. No new financials or strategic updates disclosed in the 8-K. Filing furnished under Regulation FD.
8-K
Enovis HR chief retiring
Enovis announced on December 10, 2025, that SVP and Chief HR Officer Patricia Lang will retire from her executive role on April 3, 2026, shifting to advisory duties until full retirement on April 3, 2027. Laura Singleton, VP HR for the Reconstructive segment since the 2019 DJO acquisition, steps in as successor. Lang's transition deal keeps her salary full for six months, then cuts it up to 50%. Smooth handoff preserves HR continuity.
8-K
Enovis extends debt maturities
Enovis extended its $1.1B revolving and $700M term loan facilities to December 8, 2030, with a springing maturity if liquidity falls below 125% of senior unsecured convertible notes. Lenders Truist, DNB Capital, and Sumitomo Mitsui joined; proceeds repaid $335M revolving debt, leaving $167M outstanding. Covenants eased for acquisitions over $300M.
BSX
Boston Scientific Corporation
92.95+0.76
CNMD
CONMED Corporation
39.20-1.12
DYNT
Dynatronics Corp.
0.04+0.00
ECIA
Encision, Inc.
0.15+0.00
EW
Edwards Lifesciences Corporatio
85.32+1.94
NAOV
NanoVibronix, Inc.
4.02-0.29
NVNO
enVVeno Medical Corporation
0.32+0.01
OFIX
Orthofix Medical Inc.
15.55-0.16
VYCO
Vycor Medical, Inc.
0.16+0.00
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52